The Association between Metformin Use and Risk of Developing Severe Dementia among AD Patients with Type 2 Diabetes
Open Access
- 30 October 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (11) , 2935
Abstract
This study explores the potential impact of metformin on the development of severe dementia in individuals with Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM). With an emerging interest in the role of the APOE genotype in mediating metformin’s effects on cognitive decline in AD patients, we sought to investigate whether metformin usage is associated with a reduced risk of severe dementia. Using data from the National Alzheimer’s Coordinating Center (NACC) database (2005–2021), we identified 1306 participants with both AD and T2DM on diabetes medications. These individuals were categorized based on metformin usage, and a propensity score-matched cohort of 1042 participants was analyzed. Over an average follow-up of 3.6 years, 93 cases of severe dementia were observed. A Kaplan–Meier analysis revealed that metformin users and non-users had similar probabilities of remaining severe dementia-free (log-rank p = 0.56). Cox proportional hazards models adjusted for covariates showed no significant association between metformin usage and a lower risk of severe dementia (HR, 0.96; 95% CI, 0.63–1.46; p = 0.85). A subgroup analysis based on APOE ε4 carrier status demonstrated consistent results, with metformin use not correlating with a reduced severe dementia risk. In conclusion, our findings from a substantial cohort of AD and T2DM patients suggest that metformin usage is not significantly associated with a decreased risk of severe dementia. This observation persists across APOE ε4 carriers and non-carriers, indicating a lack of genotype-mediated effect.Keywords
Funding Information
- Competitive Medical Research Fund of the UPMC Health System (R56AG074951)
- University of Pittsburgh (R56AG074951)
- National Institute on Aging of the National Institutes of Health (R56AG074951)
This publication has 37 references indexed in Scilit:
- DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trialThe American Journal of Clinical Nutrition, 2013
- Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapyNature Reviews Neurology, 2013
- Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive declineJournal of Clinical Investigation, 2012
- Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's diseaseNature Genetics, 2009
- Impaired insulin secretion increases the risk of Alzheimer diseaseNeurology, 2008
- Type 2 Diabetes Mellitus and Cognitive Decline in Two Large Cohorts of Community‐Dwelling Older AdultsJournal of the American Geriatrics Society, 2008
- The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease CentersAlzheimer Disease & Associated Disorders, 2006
- The apolipoprotein E ϵ4 allele causes a faster decline of cognitive performances in Down's syndrome subjectsJournal of the Neurological Sciences, 1997
- Apolipoprotein E, ɛ4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal regionHuman Molecular Genetics, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984